Sun, Feb 1, 2015, 2:14 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Echo Therapeutics, Inc. Message Board

razortruth2001 14 posts  |  Last Activity: Dec 31, 2014 8:02 AM Member since: Mar 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Old data

    by jonesallen234 Dec 30, 2014 1:20 PM
    razortruth2001 razortruth2001 Dec 31, 2014 8:02 AM Flag

    It''s not a reformulation of Levodopa, it's a novel and patented delivery system! And you shorts are so desperate that a poster made up a brokerage firm supposedly giving NDRM a sell rating target of 8. It's quite wrong to make up stuff like that on purpose on the message board because some naive people may believe that kind of lie.

    Sentiment: Strong Buy

  • NDRM just IPO'd last month! That was a public raise! I don't think they will raise more funds through a stock raise now because they just did it last month!

    Sentiment: Strong Buy

  • Reply to

    Misunderstanding, I thibk

    by roosterly9 Dec 30, 2014 1:36 PM
    razortruth2001 razortruth2001 Dec 30, 2014 1:45 PM Flag

    Yes it is a simple innovation THAT IS PATENTED and it will change, very soon, the EFFICACY of levodopa, an already proven therapy for parkinson diseases. Patients will demand the pump over the uneven efficacy of pill therapy! Does this explain why this news is so important for those afflicted with levodopa receptive brain disease?

    Sentiment: Strong Buy

  • razortruth2001 razortruth2001 Dec 30, 2014 1:25 PM Flag

    The trial data that the market is reacting to was released early this morning before the market opened. The trial data cleared benchmarks safety effects as well as steady efficacy. It's funny that such a simple idea as steady blood levodopa administration would be such a blockbuster innovation. The ups and downs of non-continuous levodopa therapy for central nervous system disease, most importantly parkinson disease and related levodopa therapy responsive diseases originating in the brain, cry out for a more steady-state way to SAFELY administer levodopa dosages past the blood-brain barrier. Hats off to Dr. Schleisenger in Israel for simplifying an important goal into an important clinical innovation. Not only will severe parkinson disease sufferers benefit, but milder cases will no doubt (on or off label) benefit from NeuroDerm's simple yet important concept for continuously steady levodopa therapy for debilitating brain degenerative disease that is becoming more and more of an epidemic as our life spans become longer and longer.

    Sentiment: Strong Buy

  • razortruth2001 by razortruth2001 Dec 21, 2014 8:55 AM Flag

    NVGN used bucket shop hc wainwright to do their public raise. Disgraced management from the fly by night Rodman and Renshaw pipe dealer have been taken in by hc wainwright. These pipe players prey on small investors like you to be the liquidity for these often unconscionable uses of financial money raising for near dead companies. Disgraced Josephthal was a predecessor to this old Boston name's entry into scheming micro cap pipe raises. Josephthal took over Rosenkratz lynn and ross, another rapacious wall street bucket shop.

  • razortruth2001 by razortruth2001 Dec 16, 2014 3:38 PM Flag

    Nothing is in the clinic yet. The press release says they won't even pursue this hunch of a melanoma candidate until more funds are raised. Looking at the 5 year chart, this company was in the millions - the sickest chart I've ever seen. Yesterday it was trading in the 2's or 1's. This company is dilution city. Congrats on hype by headline, guys at NVGN. Basically nothing new has happened other than a hypothesis that brain cancer and skin cancer are related.

  • Reply to

    8 Months-9Months and ?? we thought app. was in ?

    by redfrogkm Dec 11, 2014 11:10 AM
    razortruth2001 razortruth2001 Dec 14, 2014 1:51 PM Flag

    The big news is that FOLD is way in the lead for advanced breakthroughs in lysosomal storage metabolic disease. SGMO is not nearly as advanced as is FOLD!

  • Reply to

    Seems like it will start to drop back from tomorrow

    by stash_fry Nov 12, 2014 11:10 AM
    razortruth2001 razortruth2001 Nov 12, 2014 3:29 PM Flag

    Quick, correct me if I'm wrong, you've been here since the scam stock ANX with CoFactor. How can you believe in these people, Levine proteges Culley and Karen?

    Sentiment: Strong Sell

  • razortruth2001 razortruth2001 Nov 6, 2014 8:20 PM Flag

    Nice to see you too Rory. Had to comment for the benefit of potential newbies on the scalping of common shareholder value methods Culley and Keren have resorted to following the original ANX methods. At least MSTX is following a new path of researching among vascular/circulatory and blood abnormality diseases such as sickle cell disease and inflammatory conditions at the cellular level involving endothelium mediated vasoconstrictive conditions instead of their me-too vit B pro-drug pathetic attempt to fool people into thinking they would be major chemotherapy players for multiple categories of cancer treatment with that CoFactor stuff. Whatever, they are still ripping off the common shareholders, as they've done for years. $10 of ANX back in 1999 must now be worth about five cents! How's that for preserving a company at the expense of its common shareholders?

  • Reply to

    This finanacing

    by kitkatwhun Nov 6, 2014 9:01 AM
    razortruth2001 razortruth2001 Nov 6, 2014 10:10 AM Flag

    What are you talking about trying to pump this shareholder equity destroying company when you say now they have better quality institutional investors? Cowen and Company is a 2014 bucket shop, which means it is about as greedy as Wall Street gets in taking out a percentage for themselves and themselves only from this latest financing/dilution Culley and Cowen have done to the long suffering common shareholders of ANX/MSTX. This whole dilution business with microcap financiers makes decent people squirm in disgust. Do you know what is decent about how MSTX/ANX treats its common shareholders? Humm....
    There is nothing decent about how MSTX/ANX treats its shareholders!

  • I was posting on CDTI about how using Cowen for financing is a bad sign because this small cap to micro cap financier has a large vig for itself in these deals that is generally quite unfair to the common share shareholders like you. Culley is continuing in the ANX tradition of destroying common shareholder value by using slimy money raising methods and contacts Does Culley think Mast will pass the stink test because it changed its name from ANX? He's proving with this Cowen raise that MSTX is ANX.

  • razortruth2001 razortruth2001 Nov 4, 2014 3:28 PM Flag

    Cowen is known as an unfair to shareholder Wall Street microcap to small mid-cap financier. Small public shareholders like you get hurt when Cowen does financings in small companies. Cowen will never stop gouging, indirectly, small shareholders like you and me until companies like CDTI stop using them.

  • This is bad CDTI associates itself with Cowen. It means their technology patents are not A1 quality since they are relying on a low class financier to float stock.

  • razortruth2001 by razortruth2001 Nov 4, 2014 12:38 PM Flag

    cowen did the financing for CDTI. That means CDTI is sleazy enough to have to use a bucket shop low life wall street banker.

ECTE
2.06-0.03(-1.24%)Jan 30 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.